Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

Johnson & Johnson announced that the Tremfya (guselkumab) phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing ...

In January, they were overtaken by Novartis’ Pluvicto and Johnson & Johnson’s Tremfya; last month, it was Novo Nordisk’s Wegovy and J&J’s immunology med that leapfrogged over the previous ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. Findings from the Phase ...

Credit: Oporty786 / Shutterstock. US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...